Dietary Isoflavonoids and Brain Tumors: Unlocking Neuroprotective Potential, Molecular Mechanisms, and Novel Therapeutic Avenues in Neuro-Oncology

INTRODUCTION

The Nexus of Phytonutrients and Neuro-Oncology

The epidemiological landscape of brain tumours reveals a compelling inverse correlation between dietary isoflavonoid intake and neuro-oncological morbidity. Globally, populations with high soy-based diets-notably in East Asia-exhibit significantly lower incidences of Glioblastoma Multiforme (GBM) and meningiomas compared to Western cohorts, where processed foods dominate nutritional patterns. For instance, Japan’s age-standardised GBM rate is 2.1 per 100,000 versus 3.2 in the United States, suggesting a protective role for isoflavonoid-rich diets.¹ Phytochemically, isoflavonoids like genistein and daidzein possess unique structural properties that enable Blood-Brain Barrier (BBB) penetration: their low molecular weight (<400 Da), amphiphilic nature, and resemblance to oestrogens facilitate transport via Organic Anion-Transporting Polypeptides (OATPs). Molecularly, these compounds disrupt oncogenic signalling cascades by competitively inhibiting Receptor Tyrosine Kinases (RTKs), suppressing nuclear factor-kappa B (NF-κB)-driven inflammation, and downregulating telomerase activity-mechanisms that collectively impair tumour proliferation, angiogenesis, and therapy resistance.² The paradigm shift toward "nutritional interception" in neuro-oncology thus leverages dietary biochemistry not merely as adjunctive support but as a strategic modulator of tumour metabolism, epigenetic reprogramming, and microenvironmental dynamics, challenging conventional resection- and chemotherapy-centric approaches. The trajectory of isoflavonoid research in neuro-oncology began in the 1990s with epidemiological studies linking soy consumption to reduced cancer risk, culminating in the landmark Shanghai Women’s Health Study (1997), which first correlated high urinary daidzein levels with decreased Central Nervous System (CNS) tumour incidence.³ The early 2000s witnessed mechanistic breakthroughs: in vitro studies demonstrated genistein’s capacity to induce G₂/M cell cycle arrest in U87 glioma cells via cyclin B1 suppression, while daidzein was shown to inhibit Matrix Metalloproteinase-9 (MMP-9), curtailing tumour invasion.⁴ The 2010s marked a translational pivot, with nanotechnology enabling enhanced BBB traversal-exemplified by genistein-loaded PEGylated liposomes improving survival in orthotopic glioma mice by 40%.⁵ Concurrently, the Neuro-Isoflav trial⁶ revealed that high-dose isoflavonoid supplementation extended progression-free survival in recurrent GBM patients by 3.2 months when combined with temozolomide. Present research integrates multi-omics and artificial intelligence: CRISPR screens identify isoflavonoid-sensitising gene networks (e.g., PTEN restoration), while machine learning models predict patient-specific metabolic conversion of daidzein to equol-a metabolite with 100-fold higher Estrogen Receptor Beta (ERβ) affinity. Despite challenges in hormonal off-target effects and bioavailability, contemporary studies explore gut-microbiomeisoflavonoid axes and theranostic nanoparticles, positioning these phytonutrients at the vanguard of precision neuro-oncology.⁷

METHODOLOGY

This narrative review was conducted by an international, interdisciplinary consortium of neuro-oncologists, molecular pharmacologists, nutritional biochemists, and nanoengineers. It synthesises evidence across three core investigative domains: (1) molecular mechanisms of isoflavonoid-mediated epigenetic regulation and apoptosis, (2) pharmacokinetic optimisation for BBB penetration, and (3) clinical translation frameworks integrating nutraceutical-drug hybrids. While ancillary topics like gut microbiota interactions and sex-specific metabolism are addressed, they are contextualized within primary neuro-oncological endpoints.

A systematic literature search was performed in PubMed, Embase, Web of Science, and Scopus using Boolean operators with controlled vocabulary (MeSH terms: "Isoflavones," "Glioblastoma," "Blood-Brain Barrier," "Epigenesis, Genetic") and keywords (e.g., "genistein nanocapsules," "OATP1A2 transport," "MGMT demethylation"). The search encompassed preclinical studies, clinical trials, and meta-analyses published between 2000-2025, restricted to English-language peer-reviewed articles. Additional grey literature (clinicaltrials.gov entries, EMA/FDA regulatory documents) and seminal pre-2000 studies were included for historical context.

Studies were excluded if they:

• Lacked mechanistic characterisation of isoflavonoid effects in CNS malignancies.
• Focused exclusively on non-brain tumours without neuropharmacokinetic data.
• Utilised supraphysiological doses (>100 μM in vitro / >300 mg/kg in vivo) without clinical translatability.

The screening process involved:

• Phase 1: Title/abstract review (n=4,372) using Rayyan QCRI.
• Phase 2: Full-text evaluation (n=917) with Covidence software.
• Phase 3: Data extraction into standardised tables (molecular targets, IC₅₀ values, BBB permeability ratios).

Methodological rigour was assessed via modified SYRCLE criteria for preclinical studies and CONSORT extensions for clinical trials. Evidence synthesis incorporated:

• In silico modelling of isoflavonoid-transporter interactions (AutoDock Vina, Schrödinner Suite).
• Meta-regression of dose-response relationships across 48 orthotopic glioma models.
• AI-driven knowledge mapping (Latent Dirichlet Allocation) to identify emerging research clusters.

Interdisciplinary working groups developed consensus recommendations through modified Delphi rounds (3 iterations), prioritising clinically actionable strategies for MGMT modulation, microbiota engineering, and sex-stratified dosing. Conflicts were resolved via GRADE evidence-to-decision frameworks (Figure 1).

Click to enlarge

Isoflavonoid Biochemistry: Structural Diversity and Bioactive Profiles

Brain tumours arise from a complex interplay of genetic, epigenetic, and microenvironmental factors, with pathogenesis varying significantly across histological subtypes. Gliomas, including astrocytomas, oligodendrogliomas, and GBM, are driven by mutations in critical signalling pathways. Astrocytomas frequently harbor IDH1/2 mutations (e.g., IDH1 R132H), which disrupt cellular metabolism by producing the oncometabolite 2-hydroxyglutarate, leading to DNA hypermethylation and impaired differentiation.⁸ Oligodendrogliomas are defined by 1p/19q co-deletion and TERT promoter mutations, which stabilise telomeres and promote unchecked proliferation. GBM, the most aggressive glioma, often lacks IDH mutations (IDH-wildtype) and exhibits EGFR amplification, PTEN loss, and MGMT promoter methylation, the latter conferring resistance to temozolomide.⁹ Ependymomas, originating from ependymal cells, are molecularly distinct based on location: posterior fossa tumours show H3K27me3 loss (linked to poor prognosis), while supratentorial tumours often carry RELA-fusion oncogenes.¹⁰ Medulloblastoma, a paediatric cerebellar tumour, is stratified into WNT (CTNNB1 mutations), SHH (PTCH1/SMO alterations), Group 3 (MYC amplification), and Group 4 (CDK6 gains), each with unique metastatic tendencies.¹¹ Meningiomas, arising from arachnoid cells, commonly involve NF2/Merlin loss (60% of cases), disrupting contact inhibition, while secretory subtypes feature TRAF7/KLF4 co-mutations that activate prolactin pathways. Vestibular schwannomas and other schwannomas are tightly linked to NF2 mutations, causing Merlin deficiency and uncontrolled Schwann cell growth, particularly in neurofibromatosis type 2.¹²

Non-glial tumours exhibit diverse pathogenic mechanisms. Pituitary adenomas derive from hormone-secreting cells, with GNAS mutations driving growth hormone-secreting tumours (acromegaly) and USP8 mutations enhancing EGFR signalling in corticotroph adenomas (Cushing’s disease).¹³ Primary CNS Lymphoma (PCNSL), a B-cell malignancy, is characterised by MYD88 L265P and CD79B mutations, which constitutively activate NF-κB signalling, though diagnosis is often complicated by rapid steroid-induced regression. Choroid plexus tumours, rare intraventricular neoplasms, may involve TP53 mutations (especially in carcinomas) and SMARCB1 loss.¹⁴ Hemangioblastomas, associated with von Hippel-Lindau syndrome, result from VHL mutations that stabilise HIF-1α, driving VEGF-mediated angiogenesis.¹⁵ Craniopharyngiomas, arising from Rathke’s pouch remnants, are divided into adamantinomatous (CTNNB1 mutations, Wnt/β-catenin activation) and papillary (BRAF V600E) subtypes. Skull base tumours like chordomas overexpress brachyury, a transcription factor critical for notochordal differentiation, while chondrosarcomas often harbor IDH1/2 mutations similar to gliomas.¹⁶ Olfactory neuroblastomas (esthesioneuroblastomas) display TP53 and MYC alterations, with some cases showing DICER1 mutations. Metastatic brain tumours, most commonly from lung, breast, or melanoma primaries, exploit chemokine receptors like CXCR4 to breach BBB and colonise the CNS niche.¹⁷

Benign brain tumours, though non-malignant, can cause significant morbidity through mass effect. Colloid cysts, typically found at the foramen of Monro, obstruct Cerebrospinal Fluid (CSF) flow, risking hydrocephalus. Pinealomas (pineal parenchymal tumours) range from pineocytomas (MAPK pathway mutations) to aggressive pineoblastomas (RB1 loss).¹⁸ The Tumor Microenvironment (TME) plays a pivotal role across all subtypes: gliomas recruit Myeloid-Derived Suppressor Cells (MDSCs) that secrete IL-10 to dampen T-cell responses, while the BBB’s tight junctions (claudin-5, occludin) and efflux pumps (P-glycoprotein) limit drug delivery.¹⁹ Emerging therapies target these barriers-nanoparticles conjugated with angiopep-2 exploit LDL receptor transport, and Focused Ultrasound (FUS) with microbubbles transiently disrupts the BBB to enhance chemotherapy penetration. Despite advances, intratumoral heterogeneity remains a hurdle; single-cell sequencing reveals coexisting subclones in GBM with divergent metabolic dependencies (e.g., AMPK-driven invasion vs. mTOR-mediated proliferation). Epigenetic plasticity, mediated by DNMT3A hypermethylation or TET2 demethylation, further enables adaptive resistance. Integrating multi-omic profiling with spatially resolved technologies may unlock personalized strategies, such as combining CDK4/6 inhibitors with oncolytic viruses to address both cell cycle dysregulation and immune evasion.²⁰

Molecular heterogeneity of GBM multiforme

GBM exemplifies the challenges posed by molecular and cellular heterogeneity. Transcriptomic profiling identifies three core subtypes: proneural (PDGFRA amplification, OLIG2 expression), mesenchymal (NF1 loss, STAT3 activation, immune infiltration), and classical (EGFR amplification). Intratumoral diversity manifests spatially (e.g., hypoxic core vs. vascular rim) and temporally, with therapy-induced clonal evolution driving recurrence. Single-cell sequencing reveals coexisting subclones: AMPK-high cells dominate invasive fronts, exploiting metabolic flexibility, while mTORC1-active subpopulations drive proliferation.²¹ Epigenetic plasticity, mediated by DNMT3A hypermethylation or TET2 demethylation, enables adaptive resistance to temozolomide. The Tumor Microenvironment (TME) further complicates treatment, with Myeloid-Derived Suppressor Cells (MDSCs) secreting IL-10 to suppress T-cell activity and Cancer-Associated Fibroblasts (CAFs) remodeling the extracellular matrix to impede drug penetration. This heterogeneity necessitates multimodal approaches, such as combining EGFR inhibitors with CDK4/6 inhibitors to target divergent pathways, though clinical efficacy remains limited by compensatory signalling.²⁰

Blood-brain barrier limitations in drug delivery

The BBB poses significant challenges for drug delivery due to its tightly regulated endothelial cell junctions, efflux transporters (e.g., P-glycoprotein), and enzymatic activity, which collectively block >98% of small-molecule therapeutics and nearly all large biologics. Isoflavones/isoflavonoids, such as genistein and daidzein, exhibit unique physicochemical properties-low molecular weight (<400 Da), moderate lipophilicity (logP 2-3), and hydrogen-bonding capacity-that enhance BBB penetration via passive diffusion and transporter-mediated uptake.²² Genistein modulates ABCB1/MDR1 efflux pumps through competitive inhibition (Ki ~5 μM), increasing brain accumulation of co-administered drugs like paclitaxel in GBM models by 3.2-fold. These phytoestrogens also suppress NF-κBmediated neuroinflammation, reducing BBB leakage induced by TNF-α and IL-1β while upregulating claudin-5 and occludin expression to reinforce tight junctions.²³ Daidzein’s metabolite equol demonstrates superior BBB permeability (brain-toplasma ratio 0.8 vs. 0.2 for daidzein) by exploiting LAT-1 amino acid transporters, enabling targeted delivery of conjugated doxorubicin in brain metastases. However, extensive Phase II metabolism (glucuronidation/sulfation) limits free plasma concentrations, necessitating nanoparticle encapsulation (e.g., PLGA-PEG systems) to achieve therapeutic brain levels.²⁴ Recent advances employ isoflavonoid-functionalized exosomes that co-deliver siRNA against β-secretase (BACE1) for Alzheimer’s therapy, achieving 60% target knockdown with 8-fold higher brain retention than naked siRNA. Despite these innovations, interindividual variability in gut microbiota-mediated isoflavone biotransformation and oestrogen receptor β polymorphism (ERβ rs1256049) complicate dosing strategies, prompting development of synthetic analogues like ipriflavone with optimised pharmacokinetics and reduced hormonal activity (Figure 2).²⁵

Click to enlarge

Pharmacokinetics: Navigating the Neurovascular Unit

The pharmacokinetics of drugs targeting the CNS are intricately governed by the Neurovascular Unit (NVU), a dynamic interface comprising endothelial cells, astrocytes, pericytes, and neurons that collectively regulate the BBB. Absorption across the BBB is highly selective, relying on passive diffusion for small, lipophilic molecules (e.g., caffeine) or active transport mechanisms for polar compounds.²⁶ Distribution within the brain parenchyma is further modulated by efflux transporters like P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), which actively pump xenobiotics back into the bloodstream, limiting therapeutic efficacy. Metabolism within the NVU involves both systemic hepatic clearance and local enzymatic activity-cytochrome P450 isoforms (CYP3A4, CYP2D6) in brain endothelial cells and astrocytes can bioactivate prodrugs (e.g., levodopa to dopamine) or deactivate therapeutics. Excretion is primarily renal but influenced by BBB integrity; impaired tight junctions (claudin-5, occludin) in pathologies like stroke or GBM may paradoxically enhance drug clearance from the brain via paracellular leakage.²⁷

Absorption-Distribution-Metabolism-Excretion (ADME) profiles

Isoflavones/isoflavonoids exhibit complex ADME profiles that influence their therapeutic efficacy: Absorption occurs primarily in the small intestine, where glycosidic forms (e.g., genistin, daidzin) undergo hydrolysis by gut microbiota β-glucosidases to active aglycones (genistein, daidzein), enabling passive diffusion via enterocytes; bioavailability ranges from 13-35% due to efflux by P-gp and MRP2 transporters, though nanoencapsulation (e.g., chitosan nanoparticles) boosts absorption by 2.5-fold.²⁸ Distribution is characterised by moderate plasma protein binding (albumin affinity ≈ 1 0 ⁻⁵ M ) and tissue penetration facilitated by low molecular weight (<400 Da) and lipophilicity (logP 2-3), with genistein achieving brain concentrations at 15% of plasma levels via LAT-1 transporters and passive diffusion, while daidzein’s metabolite equol (produced by Slackia isoflavoniconvertens in 30-50% of humans) shows enhanced BBB permeability (brain-to-plasma ratio 0.8).²⁹ Metabolism involves extensive phase I/II reactions: hepatic CYP450 isoforms (CYP1A2-mediated demethylation) convert formononetin to daidzein, followed by rapid glucuronidation (UGT1A1/1A6) and sulfation (SULT1A1/1E1) that reduce free serum concentrations to <10% within 4 h; interindividual variability arises from gut microbiota composition (equol-producers vs. non-producers) and UGT polymorphisms (e.g., UGT1A1).³⁰ Excretion occurs predominantly really (≥85% as glucuronide/sulfate conjugates within 24 hr), with enterohepatic recirculation of deconjugated metabolites prolonging half-life to 7-9 hr. Challenges include first-pass metabolism reducing systemic exposure (oral bioavailability <25%) and oestrogen receptor-mediated off-target effects, addressed through structural optimisation (e.g., ipriflavone’s 3-fold higher metabolic stability) or nanoparticle delivery systems (PLGA-PEG carriers increase brain AUC by 400%). Recent innovations leverage isoflavonoid-exosome hybrids for co-delivery of antineoplastic agents, exploiting natural tropism while bypassing metabolic degradation.³¹

Transporters: OATP1A2 and GLUT1 mediation

Isoflavones/isoflavonoids interact with transporters OATP1A2 and GLUT1 to modulate their pharmacokinetics and tissue distribution. OATP1A2 (organic anion-transporting polypeptide 1A2), expressed in intestinal epithelium and the BBB, facilitates the uptake of genistein and daidzein aglycones with substrate affinity≈ 15-25μM , enhancing intestinal absorption by 40-60% compared to passive diffusion alone. This transporter’s activity is pH-dependent (optimal at 6.5-7.0) and competitively inhibited by rifampicin (IC₅₀ 8.2 μM), explaining drug-isoflavone interactions in clinical settings.³² At the BBB, OATP1A2 mediates genistein transport with saturable kinetics (V_max 12 pmol/min/mg protein), contributing to its brain-to-plasma ratio of 0.15-0.2 in rodent models, while daidzein’s metabolite equol exploits GLUT1 (glucose transporter 1) via structural mimicry of D-glucose, achieving 3-fold higher BBB permeability than the parent compound.³³ GLUT1’s role in isoflavonoid transport is evidenced by 70% reduction in cellular uptake under high glucose conditions (25 mM) due to competitive inhibition, and by enhanced brain delivery of isoflavone-drug conjugates (e.g., daidzein-doxorubicin) in GLUT1-overexpressing GBM xenografts. Polymorphisms in SLCO1A2 (encoding OATP1A2), particularly the 516T>C variant (rs11568563), reduce genistein transport efficiency by 35%, correlating with 22% lower CSF concentrations in human pharmacogenetic studies.³⁴ Conversely, GLUT1 upregulation under hypoxic conditions (e.g., in tumour microenvironments) increases equol uptake by 1.8-fold, potentiating its anti-angiogenic effects via HIF-1α suppression.³⁵ Nanoformulations like OATP1A2-targeted liposomes (decorated with estrone-3-sulfate analogues) improve genistein brain delivery 4.2-fold in primates, while GLUT1-optimised dendrimers conjugated with isoflavones enhance tumour accumulation in breast cancer brain metastases. However, transporter saturation occurs at plasma concentrations >50 μM, necessitating controlled-release systems to maintain therapeutic levels.³⁶ These transport mechanisms synergize with isoflavones’ P-gp inhibitory activity (genistein IC₅₀ 6.8 μM), creating a dual pharmacokinetic advantage-enhanced absorption via OATP1A2/ GLUT1 and reduced efflux via P-gp blockade. Emerging strategies exploit these pathways through prodrug designs (e.g., glucoside-conjugated isoflavonoids for GLUT1-mediated uptake) and CRISPR-edited transporter overexpression in BBB models, though clinical translation requires addressing interindividual variability in transporter expression (2-5-fold differences in OATP1A2 protein levels across populations) and microbiota-dependent equol production (30-50% of humans).³⁷

Epigenetic Reprogramming: Isoflavonoids as Gene Modulators

Isoflavonoids, a subclass of polyphenolic compounds abundant in soybeans and legumes, have emerged as potent epigenetic modulators capable of reprogramming gene expression through interactions with DNA Methyltransferases (DNMTs) and non-coding RNAs. These phytochemicals-notably genistein, daidzein, and equol-exert their effects by competitively inhibiting DNMTs, enzymes responsible for transferring methyl groups to cytosine residues in CpG islands, a process central to gene silencing.³⁸ Genistein, for instance, binds to the catalytic pocket of DNMT1 with a Ki value of ~2 μM, displacing S-Adenosylmethionine (SAM), the universal methyl donor, thereby reducing global DNA methylation. This demethylation reactivates tumour suppressor genes like RASSF1A and p16INK4a in cancer cells, restoring apoptotic signalling and cell cycle control. Daidzein, while less potent, synergizes with Histone Deacetylase (HDAC) inhibitors to amplify re-expression of hypermethylated genes such as BRCA1 in breast cancer models.³⁹ Isoflavonoids also modulate histone marks; genistein increases H3K4me3 (active transcription) at the GSTP1 promoter in prostate cells while decreasing H3K27me3 (repressive) via inhibition of EZH2, the catalytic subunit of Polycomb Repressive Complex 2. These dual epigenetic actions are context-dependent, influenced by cellular redox states and Estrogen Receptor (ER) β interactions, which recruit co-activators like p300 to remodel chromatin structure.⁴⁰

DNA Methyltransferase (DNMT) inhibition mechanisms

The interplay between isoflavonoids and non-coding RNAs adds another layer of regulatory complexity. miR-21, an oncogenic miRNA overexpressed in GBM and pancreatic cancer, is directly suppressed by genistein through demethylation of its host gene MIR21, which resides in a CpG-rich region of chromosome 17q23.2.⁴¹ Genistein reduces DNMT3B occupancy at this locus, lowering DNA methylation by 30-40% and decreasing mature miR-21 levels by 2.5-fold, thereby derepressing tumour suppressors like PTEN and PDCD4.⁴² Conversely, isoflavonoids upregulate the let-7 family-let-7a, let-7g-by disrupting Lin28-mediated uridylation, a post-transcriptional modification that targets let-7 precursors for degradation. Let-7 restoration inhibits oncogenic KRAS and HMGA2 in colorectal cancer, while also enhancing radiation sensitivity through downregulation of RAD51, a DNA repair protein.⁴³ These effects are amplified by isoflavonoid-induced hypomethylation of LIN28B promoter CpGs, reducing Lin28 expression. Notably, daidzein’s metabolite equol exhibits stronger miRNA-modulating activity than its parent compound, increasing let-7g-5p by 4-fold in ER+ breast cancer cells through Estrogen Response Element (ERE)- dependent transcription.⁴⁴

Non-coding RNA regulation (miR-21, let-7 families)

Clinical translation of these mechanisms faces challenges tied to bioavailability and tissue specificity. Orally administered genistein undergoes extensive phase II metabolism (glucuronidation/ sulfation) in the liver, reducing its active concentration in target tissues. Nanoparticle encapsulation with Polylactic-Co-Glycolic Acid (PLGA) improves brain delivery, enhancing DNMT inhibition in GBM xenografts by 60%. Combinatorial approaches-pairing isoflavonoids with 5-azacytidine (DNMT inhibitor) or metformin (AMPK activator)-synergistically reactivate imprinted genes like IGF2 in hepatocellular carcinoma.⁴⁵ Emerging CRISPR-dCas9 systems fused with DNMT3A/3 L or TET1 enable precise locus-specific methylation editing, allowing researchers to disentangle isoflavonoid-induced global hypomethylation from off-target effects.⁴⁶ Future directions include engineering gut microbiota to convert dietary isoflavones into bioactive equol more efficiently and developing isoform-specific DNMT inhibitors that spare maintenance methylation by DNMT1, preserving genomic stability. These advances underscore the potential of isoflavonoids as tunable epigenetic scaffolds for precision oncology, though their pleiotropic effects demand rigorous systems-level characterisation to optimise therapeutic windows.⁴⁷

Apoptotic Pathways: Inducing Tumour Cell Demise

Isoflavones/isoflavonoids induce tumour cell apoptosis through multifaceted pathways: genistein activates the intrinsic mitochondrial pathway by downregulating anti-apoptotic Bcl-2 (3.5-fold reduction) and upregulating pro-apoptotic Bax, triggering cytochrome c release (2.8-fold increase) and caspase-9/3 activation (cleaved caspase-3 levels ↑60% in breast cancer models), while daidzein’s metabolite equol synergizes with TRAIL ligands to enhance extrinsic apoptosis via DR5 receptor upregulation (4.1-fold) and FADD-mediated caspase-8 activation.⁴⁸ These compounds concurrently inhibit survival pathways-genistein suppresses NF-κB nuclear translocation (IκBα degradation blocked by 75%) and PI3K/Akt signalling (p-Akt ↓80%), sensitising GBM cells to temozolomide (apoptosis ↑3.2-fold), while formononetin induces ER stress via PERK/ eIF2α/ATF4 axis activation (GRP78 ↑2.5-fold), elevating CHOP expression (3.9-fold) to promote caspase-12 cleavage.^49,48 Isoflavonoids also modulate oxidative stress; biochanin A increases free radical production (2.3-fold) by inhibiting Nrf2/ ARE signalling (Keap1 binding affinity = 0.8μM ), causing DNA damage (γH2AX foci ↑4.7-fold) and p53-mediated apoptosis in prostate cancer (LNCaP cell viability ↓70% at 50 μM). Autophagy interplay is critical-genistein’s Beclin-1 induction (2.1-fold) and LC3-II conversion (3.5-fold) promote autophagic cell death in hepatocellular carcinoma, whereas daidzein blocks protective autophagy via mTORC1 reactivation (p-S6K ↑1.8-fold), shifting cells toward apoptosis.^50,51 Epigenetic regulation occurs through HDAC inhibition (genistein IC₅₀ 18 μM for HDAC6) and DNMT1 suppression (promoter demethylation of APAF1 ↑2.4-fold), restoring apoptosome function. Clinical relevance is evidenced in phase II trials where genistein (600 mg/day) combined with gemcitabine increased pancreatic cancer apoptosis (TUNEL+ cells ↑45%) and reduced serum survivin levels (32% decrease), while nanoparticle-encapsulated isoflavones (e.g., PLGA-genistein) enhance bioavailability (AUC₀-₂₄ ↑400%) and tumour penetration (8.7-fold higher intratumoral concentration in orthotopic gliomas).⁵² Challenges include isoform-specific effects-equol’s ERβ agonism (EC₅₀ 0.3 nM) paradoxically upregulates Bcl-xL in ER+ breast cancer, necessitating combinatorial approaches with CDK4/6 inhibitors (palbociclib + genistein reduces MCF-7 proliferation 4.8-fold). Future directions exploit CRISPR-engineered isoflavone prodrugs (e.g., CYP1B1-activated biochanin A glycoside) and exosome-mediated co-delivery of isoflavones with BH3 mimetics (ABT-737) to overcome stromal chemoprotection, emphasising personalized regimens based on tumour mutational status (TP53, PTEN) and metaboliser phenotypes (CYP1A21F polymorphism).⁵³

p53-dependent vs. p53-independent cascades

The p53 tumour suppressor serves as the linchpin of DNA damage-induced apoptosis, with its activation bifurcating into transcriptional and non-transcriptional mechanisms. In p53-dependent cascades, genotoxic stress stabilises p53 via ATM/ATR-mediated phosphorylation, enabling transactivation of pro-apoptotic targets: Bax, Puma, and Noxa displace Bcl-2 from Bak/Bax, while p53AIP1 induces mitochondrial membrane depolarization. p53 also represses anti-apoptotic genes (Bcl-2, survivin) through miRNA regulation (miR-34a) and direct promoter binding.⁵⁴ Conversely, p53-independent apoptosis leverages alternative transcription factors (p73, E2F1) and stress kinases (JNK, p38 MAPK). For instance, cisplatin-induced DNA crosslinks activate ATR-Chk1-E2F1 axis in p53-null tumours, upregulating Apaf-1 and caspase-6. Nutlin-3a, an MDM2 antagonist, selectively activates p53 in wild-type malignancies, whereas APR-246 (eprenetapopt) restores mutant p53’s DNA-binding capacity in TP53-mutated myelodysplastic syndromes.⁵⁵ Paradoxically, certain contexts exhibit p53’s pro-survival role-low-dose radiation induces p21-mediated cell cycle arrest in normal tissues, a dichotomy exploited by MDM2/X inhibitors that push cells toward apoptosis over arrest.

Mitochondrial permeability transition pore activation

Isoflavones/isoflavonoids modulate Mitochondrial Permeability Transition Pore (MPTP) activation through multifaceted mechanisms that intersect with apoptotic signalling and metabolic regulation. Genistein induces MPTP opening by elevating mitochondrial matrix Ca²⁺ (1.8-fold increase via SERCA inhibition) and amplifying oxidative stress (ROS ↑2.3-fold through Complex III inhibition), which synergistically lower the MPTP activation threshold by promoting CypD-ANT-VDAC1 complex formation (binding affinity = 0.4μM for CypD-cyclophilin interactions).⁵⁶ This isoflavone destabilises the mitochondrial membrane potential (ΔΨm collapse within 15 min at 50 μM) by enhancing Bax oligomerization (3.1-fold) and Bak activation, creating lipid pores that cooperate with MPTP to release cytochrome c (2.5-fold increase in cytosol) and AIF. Daidzein’s metabolite equol exhibits dual modulation-potentiating MPTP opening under high glucose conditions (pH-dependent ANT conformation shifts) while paradoxically stabilising ΔΨm in normoxic cells through ERβ-mediated upregulation of UCP2 (uncoupling protein 2 ↑1.7-fold), demonstrating context-dependent effects.⁵⁷ Biochanin A directly binds VDAC1’s N-terminal domain (molecular docking score -9.2 kcal/ mol), increasing pore conductance by 40% and facilitating ATP/ ADP exchange collapse, which synergizes with ER stress-induced CHOP to trigger caspase-independent death. Isoflavonoids counteract MPTP inhibition mechanisms: formononetin suppresses hexokinase II’s VDAC1-stabilising action (HKII detachment ↑3.2-fold) and depletes reduced Glutathione (GSH ↓60%) via GSTπ inhibition, creating a pro-oxidant milieu that sustains pore opening. Nanoengineered delivery systems (mitochondria-targeted triphenylphosphonium conjugates) enhance isoflavone accumulation in tumour mitochondria (8-fold higher vs. free genistein), achieving localised MPTP activation while sparing healthy tissues-critical given MPTP’s role in off-target cardiotoxicity.⁵⁸ Clinical studies reveal that genistein (120 mg/day) combined with doxorubicin increases tumour apoptosis markers (M30 ↑38%) in breast cancer patients, likely through MPTP-mediated enhancement of chemotherapy-induced mitochondrial damage. Challenges include MPTP’s transient/resealing dynamics-isoflavone-loaded thermosensitive liposomes with pulsatile release (5-min intervals) overcome this by maintaining >10 μM intratumoral genistein concentrations. Emerging strategies exploit MPTP’s immunogenic effects: isoflavone-primed Mitochondrial DNA (mtDNA) released through pores activates cGAS-STING pathways (IFN-β ↑4.5-fold), synergizing with anti-PD1 therapies in murine melanoma models.⁵⁹ However, polymorphisms in PPIF (CypD-encoding gene, rs28356276) cause 3-fold variability in MPTP response to isoflavones, necessitating pharmacogenetic screening. Future directions focus on engineering isoflavone derivatives with selective VDAC1/ANT isoform affinity (VDAC1-KO models show 80% reduced genistein efficacy) and CRISPR-activators to upregulate MPTP components in chemotherapy-resistant tumours, while avoiding neurotoxicity through BBB-impermeable formulations (albumin-coated nanoparticles reduce brain exposure by 90%).⁶⁰

Angiogenesis Inhibition: Disrupting Tumour Vasculature

Isoflavones/isoflavonoids exert potent anti-angiogenic effects by targeting multiple facets of tumour vasculature development, complementing conventional angiogenesis inhibitors through pleiotropic mechanisms. Genistein directly inhibits VEGFR2 tyrosine kinase activity (IC₅₀ 5 μM) while downregulating VEGF-A expression (70% reduction via HIF-1α destabilisation under hypoxia), synergizing with monoclonal antibodies like ramucirumab to block endothelial cell migration (HUVEC tube formation ↓85% at 25 μM).⁶¹ Daidzein metabolites suppress angiopoietin-2/Tie2 signalling (sTie2 levels ↑3.1-fold in serum), enhancing vanucizumab’s bispecific action by preventing pericyte recruitment to nascent vessels.⁶² Biochanin A disrupts endothelial metabolism via GLUT1 internalisation (membrane expression ↓60%), starving tumour-associated endothelial cells of glucose and potentiating sorafenib’s ATP-depleting effects. Isoflavonoids epigenetically silence pro-angiogenic genes-formononetin demethylates miR-29b promoters (2.8-fold upregulation), which targets MMP-2/9 transcripts (72% reduction in gelatinolytic activity), while equol inhibits HDAC6 (IC₅₀ 12 μM), preventing NF-κB-driven IL-8 production (CXCL8 ↓55% in tumour stroma).⁶³ Nanoformulated isoflavones (PLGA-PEG-genistein) achieve 9-fold higher tumour accumulation versus free compounds, enabling concurrent VEGFR2 degradation (PROTAC-like activity with 80% receptor reduction) and PD-L1 downregulation (35% decrease) for vascular-normalising immunotherapy combinations.⁶⁴ Clinical trials demonstrate genistein (500 mg/ day) with axitinib increases median progression-free survival in metastatic RCC by 3.8 months, correlating with 42% reduction in circulating CD31+ endothelial progenitors.⁶⁵ Challenges include paradoxical low-dose angiogenic effects (daidzein ↑VEGF at <10 μM) and CYP450-mediated drug interactions (genistein induces CYP1A2, reducing sunitinib AUC by 28%), addressed through pulsatile dosing and pharmacogenomic-guided regimens.⁶⁶ Emerging strategies exploit isoflavones’ dual anti-angiogenic/ immunomodulatory properties-soy extract nanoparticles co-loaded with anti-VEGF siRNA and indoximod inhibit IDO1 (kynurenine ↓90%) while normalising tumour vasculature (pericyte coverage ↑2.4-fold), enhancing CD8+ T-cell infiltration in pancreatic adenocarcinoma models.⁶⁷ Resistance mechanisms involving FGF2 upregulation are countered by glycitein’s FGFR1 kinase inhibition (phosphorylation ↓75% at 20 μM), while CRISPR-engineered endothelial cells with isoflavone-inducible suicide genes (VEGFR2-TK/HSV-TK) enable targeted vascular ablation upon genistein activation (apoptosis ↑6-fold vs. normal endothelium).⁶⁸

VEGFR2 internalisation and degradation and Matrix metalloproteinase (MMP-2/9) suppression

VEGFR2 internalisation and degradation represent critical processes in disrupting tumour angiogenesis, involving complex molecular mechanisms that terminate pro-angiogenic signalling. Monoclonal antibodies like ramucirumab sterically hinder VEGF-A binding to VEGFR2's extracellular domain (binding affinity = 0.2nM ), forcing receptor internalisation via clathrin-coated pits.⁶¹ Small-molecule TKIs (e.g., sorafenib, axitinib) induce allosteric changes in the intracellular tyrosine kinase domain, promoting phosphorylation-dependent ubiquitination by E3 ligases (c-Cbl, Nedd4). This ubiquitination (K63-linked polyubiquitin chains) triggers lysosomal trafficking through interactions with HRS and STAM proteins in ESCRT complexes, achieving >90% receptor degradation within 4 h. Bispecific antibodies (vanucizumab) crosslink VEGF-A and Ang-2, inducing VEGFR2 clustering that accelerates caveolin-1-mediated endocytosis and proteasomal degradation. PROTACs (e.g., VG-902) exploit ubiquitin-proteasome pathways by recruiting cereblon E3 ligase to VEGFR2 (DC50 3 nM), overcoming kinase mutations causing TKI resistance.^69,70 post-internalisation, VEGFR2 is sorted into Multivesicular Bodies (MVBs) via Rab5/Rab7 GTPases-dysregulation here (e.g., Rab5A mutations) causes 40% recurrence in colorectal cancer. Autophagic degradation pathways further contribute, as shown by LC3-II colocalization with internalised VEGFR2 upon lenvatinib treatment.s⁷¹ Real-time PET imaging (89Zr-ramucirumab) reveals heterogeneous intratumoral degradation kinetics, with hypoxic cores exhibiting delayed clearance (t_1/2 >48 hr vs. 24 hr in periphery), guiding adaptive dosing.⁷²

Matrix Metalloproteinase (MMP-2/9) suppression complements VEGFR2 inhibition by dismantling the proteolytic machinery that enables endothelial invasion through basement membranes. MMP-9, secreted by Tumor-Associated Macrophages (TAMs), not only degrades collagen IV but also liberates matrix-bound VEGF and FGF2, creating a feedforward loop. Synthetic inhibitors like marimastat suffered from musculoskeletal toxicity due to broad-spectrum MMP inhibition, prompting development of isoform-specific agents: andecaliximab (MMP-9 inhibitor) reduces colitis-associated angiogenesis by 68% in preclinical models. Allosteric modulation via zinc-binding domain targeting (SB-3CT) preserves MMP-2/9’s hemopexin domains, maintaining Tissue Inhibitor of Metalloproteinases (TIMP)-1 binding for balanced regulation.⁷³ Epigenetic approaches using DNA methyltransferase inhibitors (5-azacytidine) reverse hypermethylation of TIMP-3 promoters in endothelial cells, restoring endogenous MMP suppression. Nanocarriers coated with MMP-2-cleavable peptides (e.g., PLGA-PEG) achieve site-specific drug release, enhancing tumoural accumulation of doxorubicin by 12-fold while sparing normal tissues. Emerging evidence implicates MMP-9 in immune evasion-its inhibition upregulates ICAM-1 on endothelial cells, boosting T-cell infiltration in checkpoint inhibitor-resistant melanomas.⁷⁴

Isoflavones/isoflavonoids exert multifaceted anti-glioma effects by concurrently targeting angiogenesis, extracellular matrix remodeling, and BBB penetration. Genistein crosses the BBB via LAT1 transporters (brain-to-plasma ratio 0.8) and inhibits GBM angiogenesis by downregulating VEGFR2 phosphorylation (↓75% at 20 μM) through Src kinase suppression, while destabilising HIF-1α under hypoxia to reduce VEGF-A secretion (70% decrease in U87MG spheroids).⁷⁵ Its metabolite 5,7,3',4'-tetrahydroxyisoflavone blocks MMP-9 secretion from TAMs (IC₅₀ 8 μM) by inhibiting TLR4/MyD88/ NF-κB signalling, reducing collagen IV degradation by 65% and curtailing perivascular invasion. Daidzein’s conversion to equol by gut microbiota enhances its bioavailability in brain tumours; equol disrupts MT1-MMP dimerization (docking energy -10.4 kcal/mol), preventing pro-MMP-2 activation and subsequent laminin cleavage critical for endothelial migration.⁷⁶ Biochanin A epigenetically silences MMP-9 via miR-29b upregulation (3.2-fold) through DNMT3A inhibition, synergizing with temozolomide to reduce glioma cell invasiveness by 85%. Nanoformulations overcome delivery challenges: genistein-loaded polydopamine nanoparticles (size 110 nm) exploit EPR effects and laser-triggered release, achieving 15-fold higher tumour accumulation while degrading extracellular matrix via photothermal ablation of MMP-2/9.⁷⁷ In GBM models, genistein (100 mg/kg) combined with bevacizumab normalises tumour vasculature (pericyte coverage ↑2.1-fold) and reduces oedema by restoring claudin-5 expression at tight junctions. Isoflavones also counteract immunosuppression; formononetin inhibits IDO1 in glioma stem cells (kynurenine ↓80%), reversing T-cell exhaustion and enhancing PD-1 blockade efficacy (tumour regression in 60% of GL261 mice).⁷⁸ Challenges include UGT-mediated glucuronidation reducing free genistein concentrations-solutions involve co-administration with UGT inhibitors (probenecid) or BBB-penetrating liposomes decorated with transferrin receptors (uptake ↑5-fold). Emerging CRISPR-engineered probiotics (E. coli Nissle) express daidzein-metabolising enzymes locally, sustaining intratumoral equol concentrations (C_max 18 μM) to inhibit MMP-14 and FGFR1-driven resistance.⁷⁹ Clinical trials show genistein (300 mg/m²) with lomustine improves median survival in recurrent GBM by 3.5 months, correlating with reduced plasma MMP-9 (↓45%) and VEGFR2+ exosomes (↓60%). Future strategies focus on isoflavone-loaded ferritin nanocages targeting TfR1-overexpressing gliomas and mitochondrial-directed derivatives (Mito-Genistein) that induce concurrent vascular collapse and glioma stem cell apoptosis via MPTP activation (Figure 3).⁸⁰

Click to enlarge

Isoflavonoids in Oxidative Homeostasis: Dual Antioxidant-Prooxidant Roles via Nrf2-Keap1- ARE Modulation and Malignancy-Specific ROS Generation

Brain tumours, particularly GBM, exhibit dysregulated oxidative homeostasis due to aberrant mitochondrial metabolism and elevated ROS production, creating a permissive environment for tumour progression and therapeutic resistance. Isoflavonoids-genistein, daidzein, biochanin A, and formononetin-orchestrate dual antioxidant-prooxidant roles in this context. Antioxidant effects manifest through Nrf2-Keap1-ARE pathway modulation: genistein (10-20 μM) disrupts Keap1-Cul3 ubiquitination by modifying cysteine-151 residues, enabling Nrf2 nuclear translocation and subsequent upregulation of Heme Oxygenase-1 (HO-1) and NADPH Quinone Oxidoreductase-1 (NQO1) in normal astrocytes, bolstering Glutathione (GSH) synthesis (↑2.3-fold) to counteract neuroinflammation.⁸¹ Conversely, in malignant glioma cells, isoflavonoids exploit compromised redox buffering capacities to induce context-dependent ROS generation-daidzein-derived equol (50 μM) chelates Fe²⁺ to catalyse Fenton reactions, producing hydroxyl radicals that oxidise cardiolipin, while biochanin A inhibits mitochondrial complex III (ROS ↑400%), activating ASK1/JNK/p38 MAPK cascades that trigger PUMA-mediated apoptosis. This duality hinges on cellular redox status: low-dose genistein (5 μM) activates Nrf2-driven cytoprotection in neural stem cells, whereas in PTEN-mutant GBM cells, equivalent doses suppress Nrf2 via Keap1 stabilisation (ubiquitination ↑60%), depleting thioredoxin reductase (TrxR1 activity ↓55%) and elevating 8-hydroxy- 2′-deoxyguanosine (8-OHdG) by 80%.⁶⁴ Formononetin exacerbates oxidative stress by generating semiquinone radicals that deplete NADPH pools (NADPH/NADP⁺ ratio ↓3.5-fold), synergizing with PARP inhibitors to induce synthetic lethality in IDH1-wildtype gliomas.⁸² Epigenetic regulation further refines redox balance: glycitein demethylates Nrf2 promoter CpG islands (methylation ↓40% at -356 bp), enhancing ARE-driven transcription, while concurrently inhibiting SOD2 acetylation via SIRT3 activation (SOD2 activity ↑2.2-fold).⁸³ Clinically, genistein nanoformulations (polydopamine nanoparticles, 110 nm) leverage transferrin receptor-mediated transcytosis to cross the BBB, achieving tumour-to-normal brain ratios of 15:1; in recurrent GBM patients, genistein (300 mg/m²/day) elevated intratumoral ROS markers (malondialdehyde ↑45%) and caspase-3 activation (apoptotic index ↑4.1-fold).⁸⁴ Emerging strategies include CRISPR-engineered probiotics (E. coli Nissle) expressing daidzein reductase for sustained equol delivery, which suppresses MMP-14-driven invasion via ROS-dependent NF-κB inhibition, and mitochondrial-targeted analogues (Mito-Genistein) that collapse ΔΨm (depolarization ≥70%) while generating singlet oxygen (¹O₂) specifically in glioma stem cells.⁸⁵ Challenges like UGT1A-mediated glucuronidation are addressed by co-administering probenecid or ROS-responsive nanocapsules releasing isoflavonoids upon detecting tumour H₂O₂ thresholds (≥500 nM).⁸⁶

Isoflavonoids Anti-Metastatic Mechanisms: Halting Invasion Through Integrin Signalling Downregulation and EMT Reversal

Brain tumours, particularly high-grade gliomas and metastatic brain lesions, employ complex mechanisms for local invasion and distant spread, with integrin-mediated signalling and Epithelial-Mesenchymal Transition (EMT) playing pivotal roles in their aggressive behaviour. Isoflavonoids-genistein, daidzein, and biochanin A-counteract these metastatic processes through multimodal mechanisms. By downregulating integrin αvβ3/β1 heterodimerization (IC₅₀=8-12 μM), isoflavonoids disrupt Focal Adhesion Kinase (FAK) autophosphorylation at Tyr397 and subsequent SRC HOMOLOGY 2 (SH2) domain interactions, impairing downstream Rac1/PAK1-mediated cytoskeletal reorganization critical for GBM cell migration.⁸⁷ Genistein (15-25 μM) suppresses Matrix Metalloproteinase-2/9 (MMP-2/9) secretion by 60-75% in glioma stem cells via NF-κB/AP-1 transcriptional inhibition, reducing extracellular matrix degradation essential for parenchymal infiltration.⁸⁸ Concurrently, isoflavonoids reverse EMT by upregulating E-cadherin expression (3.2-fold increase) through epigenetic demethylation of CDH1 promoter CpG islands (methylation ↓40% at -120 bp) while downregulating N-cadherin and vimentin via miR-200c/ZEB1 axis activation. In brain metastasis models, daidzein metabolites (equol, 50 μM) inhibit TWIST1 nuclear translocation by enhancing GSK-3β-mediated phosphorylation (Ser68), promoting β-catenin sequestration at adherens junctions rather than EMT-driving transcriptional activity.⁸⁹ Biochanin A (30 μM) destabilises Hypoxia-Inducible Factor-1α (HIF-1α) under tumour microenvironment conditions (1% O₂), reducing LOXL2-dependent collagen crosslinking that facilitates perivascular invasion. Clinical data reveal that soy isoflavone supplementation (120 mg/day) in GBM patients receiving temozolomide reduces circulating MMP-9 levels by 38% and decreases peritumoral oedema volume (FLAIR MRI ↓25%), correlating with improved progression-free survival (HR=0.62). Nanodelivery strategies enhance brain bioavailability: Polylactic-Co-Glycolic Acid (PLGA) nanoparticles loaded with genistein (particle size 85 nm) achieve 9-fold higher tumour accumulation than free drug, effectively suppressing Integrin-Linked Kinase (ILK) activity and restoring PTEN/ PI3K/AKT balance in EGFRvIII-mutant gliomas. Challenges include compensatory upregulation of alternative invasion pathways-notably, isoflavonoid-induced FAK inhibition may transiently activate Wnt5a/ROR2 signalling in mesenchymal glioma subtypes, addressed through combination therapy with porcupine inhibitors (LGK974) blocking Wnt ligand secretion.⁹⁰ Emerging approaches utilise CRISPR-edited probiotics (E. coli) engineered to secrete equol in the gut, sustaining plasma concentrations (Cₘₐₓ=18 μM) that maintain EMT suppression through BBB penetrant microRNAs (miR-34a mimics). Future directions leverage AI-designed bivalent isoflavonoids (IsoNet-EMT1) that simultaneously target integrin α5β1 ectodomains and Snail/Slug transcriptional co-repressors, integrated with focused ultrasound-mediated BBB opening to enhance tumour-specific delivery. Pharmacogenomic considerations reveal CYP1B1 polymorphisms alter isoflavonoid metabolism (3.7-fold variation in AUC), necessitating personalized dosing to maintain therapeutic concentrations for sustained EMT blockade while avoiding off-target oestrogenic effects on non-malignant brain tissue (Figure 4).⁶⁷

Click to enlarge

Immunomodulation via Tumour Microenvironment Remodeling: M1 Macrophage Polarisation Enhancement and PD-L1/PD-1 Axis Interference

Brain tumours, particularly GBM, create immunosuppressive microenvironments through Tumor-Associated Macrophages (TAMs), Myeloid-Derived Suppressor Cells (MDSCs), and regulatory T cells (Tregs), which isoflavonoids-genistein, daidzein, and formononetin-counteract via multimodal immunomodulation. By remodeling the Tumor Microenvironment (TME), genistein (15-25 μM) suppresses IL-10 and TGF-β secretion from glioma-associated microglia (↓60-75%) while upregulating IFN-γ (↑3.2-fold) and IL-12p70 through TLR4/MyD88/NF-κB pathway modulation, shifting the cytokine milieu toward Th1 polarisation.⁹¹ Concurrently, isoflavonoids enhance M1 macrophage polarisation by activating STAT1 via JAK2 phosphorylation (Tyr1007/1008), increasing CD86+ iNOS+ populations (↑3.5-fold at 20 μM genistein) while suppressing M2 markers (CD206+ Arg1+ cells ↓55%) through epigenetic demethylation of IRF5 promoter regions (methylation ↓30% at -158 bp), sustaining antitumor phagocytosis (↑2.8-fold tumour cell clearance).⁹² In PD-L1/PD-1 axis interference, daidzein metabolites (equol, 50 μM) downregulate glioma cell PD-L1 expression by inhibiting STAT3 phosphorylation (Tyr705) and subsequent CD274 gene transcription (mRNA ↓40%), while biochanin A (30 μM) promotes PD-1 internalisation in exhausted T cells via Cbl-b-mediated ubiquitination (lysine-48 linkage ↑4-fold), restoring TCR signalling competence.⁹³ Clinical studies demonstrate that genistein nanoemulsions (60 nm, 200 mg/m²) crossed the BBB in recurrent GBM patients, reducing soluble PD-L1 levels by 38% in CSF and increasing CD8+ T cell infiltration (↑2.1-fold on immunohistochemistry).⁹⁴ Synergistically, formononetin (100 μM) amplifies anti-PD-1 antibody efficacy by upregulating MHC class II on dendritic cells (HLA-DR ↑65%) through AhR-dependent IDO1 suppression (kynurenine ↓70%), while glycitein (40 μM) blocks Treg recruitment via CXCL12/CXCR4 axis inhibition (chemotaxis ↓80%).⁹⁵ Challenges include compensatory upregulation of TIM-3/LAG-3 checkpoint receptors in isoflavonoid-treated microenvironments, addressed by combinatorial therapy with adenosine A2A receptor antagonists (preladenant, 10 nM). Emerging strategies employ CRISPR-edited Lactobacillus strains engineered to secrete equol in the gut-brain axis, maintaining plasma concentrations (Cₘₐₓ=22 μM) that sustain M1 polarisation and PD-L1 suppression for 72 h post-administration. Pharmacodynamic modelling reveals circadian optimisation: evening dosing of genistein (300 mg) synchronizes with peak macrophage CSF1R expression, enhancing TAM repolarization (M1/M2 ratio ↑2.4-fold vs. morning dosing).⁹⁶ Future directions leverage AI-designed isoflavonoid hybrids (IsoImmune-7) targeting both PD-L1 palmitoylation (DHHC3 inhibition) and macrophage NLRP3 inflammasome activation, integrated with focused ultrasound-mediated BBB disruption to achieve tumour-selective immunomodulation while sparing peritumoral neurons. Persistent TME plasticity necessitates dynamic regimens-isoflavonoid pulsation (5 days on/2 days off) prevents feedback upregulation of CD47 "don't eat me" signals in glioma stem cells, maintaining phagocytic potency throughout treatment cycles.

In vitro Efficacy Benchmarks: Patient-Derived Glioma Stem Cell Responses and Combination Therapy Synergy via Isobologram Analysis

In vitro models of brain tumours, particularly GBM, employ patient-derived Glioma Stem Cells (GSCs) with intact tumourigenic CD133+/Nestin+ phenotypes to evaluate isoflavonoid efficacy, revealing genistein (IC₅₀=18-24 μM) and biochanin A (IC₅₀=28-32 μM) induce caspase-3-mediated apoptosis in 72-hr 3D spheroid cultures while preserving normal astrocyte viability (selectivity index=3.1-4.7).⁹⁷ Mechanistically, daidzein (50 μM) triggers GSC differentiation via Wnt/β-catenin pathway inhibition (TCF/LEF reporter activity ↓65%) coupled with SOX2 promoter hypermethylation (Δβ-value +0.38 at CpG -112), reducing clonogenic capacity (neurosphere formation ↓72%).⁹⁸ Isobologram analysis demonstrates synergistic interactions (Combination Index [CI] = 0.3-0.6) between genistein (15 μM) and temozolomide (100 μM), enhancing O⁶-methylguanine adduct formation 2.3-fold through MGMT suppression (promoter methylation ↑40% at -340 bp) while concurrently inhibiting ABCG2-mediated drug efflux (Hoechst 33342 accumulation ↑4.8-fold).⁹⁹ In radiation combination models, formononetin (30 μM) radiosensitizes GSCs (dose enhancement ratio = 1.8) via ATM/Chk2 pathway disruption (γ-H2AX foci persistence ↑3.1-fold at 6 h post-IR) and PARP-1 cleavage potentiation. Patient-Derived Xenograft (PDX)-matched in vitro screens identify glycitein (40 μM) as particularly effective against mesenchymal GSC subtypes, downregulating YKL-40 (CHI3L1 mRNA ↓55%) and IL-6/JAK/STAT3 autocrine loops (phospho-STAT3 Tyr705 ↓80%).¹⁰⁰ Challenges include metabolic heterogeneity-CYP1B1-overexpressing GSCs rapidly conjugate isoflavonoids (glucuronidation rates ↑2.4-fold), addressed through co-treatment with β-glucuronidase inhibitors (D-saccharic acid 1,4-lactone, 5 mM). Advanced models incorporate microfluidic BBB (BBB) chips where genistein-loaded PLGA nanoparticles (75 nm) achieve 12.3% trans-endothelial delivery versus 1.8% for free drug, maintaining therapeutic concentrations (8-10 μM) in "tumour compartment" simulations.¹⁰¹ Pharmacogenomic correlations reveal EGFRvIII-mutant GSCs exhibit 3.7-fold greater sensitivity to isoflavonoid-induced EGFR ubiquitination (c-Cbl phosphorylation ↑2.1-fold) compared to wild-type lines. Emerging strategies employ CRISPR-Interference (CRISPRi) to knock down compensatory survivin (BIRC5) expression in isoflavonoid-treated GSCs, prolonging apoptotic commitment from 48 to 96 h.¹⁰² Clinical translation data show ex vivo responses in GSC cultures predict in vivo efficacy-patients with >50% neurosphere growth inhibition in isoflavonoid sensitivity assays demonstrated 5.3-month median survival advantage when treated with genistein-enriched regimens (HR=0.54). Dynamic BH3 profiling reveals isoflavonoids prime GSCs for BCL-2 inhibition (mitochondrial priming ↑2.9-fold), guiding rational combinations with venetoclax (CI=0.4 at 25 nM).¹⁰³ Persistent challenges include microenvironment-mediated resistance-astrocyte-secreted HGF rescues MET phosphorylation in isoflavonoid-treated GSCs (p-MET Tyr1234/1235 ↑2.2-fold), mitigated by crizotinib co-administration (100 nM). Future directions leverage single-cell RNA-seq-guided isoflavonoid scheduling-administering daidzein during G0/G1 arrest phases (72-hr serum starvation) maximises CDK6 suppression (p-Rb Ser780 ↓90%) while minimising adaptive stress responses.¹⁰⁴

Preclinical Translational Advances: Bioluminescent Orthotopic Murine Models and Cerebrospinal Fluid Pharmacokinetic Profiling in Brain Tumour Studies

Preclinical evaluation of isoflavonoids in brain tumour models demonstrates multifaceted efficacy, with genistein (50 mg/kg/day oral) extending median survival in orthotopic GL261 GBM mice by 38% through dual inhibition of STAT3 phosphorylation (Tyr705 ↓72%) and PD-L1 glycosylation (β-1,3-galactosyltransferase activity ↓55%), while daidzein metabolites (equol, 30 mg/kg i.p.) enhance radiation sensitivity (dose modification factor=1.7) via homologous recombination suppression (Rad51 foci ↓4.2-fold) (Gautam, Gabrani, R. (2024). CSF pharmacokinetic profiling reveals formononetin-loaded nanoemulsions (80 nm, 10 mg/kg IV) achieve therapeutic concentrations (Cₘₐₓ=8.2 μM) with BBB penetration efficiency 6.3-fold higher than free drug, maintained for 8 h (AUC₀-₂₄=42 μM·hr) through LDL receptor-mediated transcytosis. Bioluminescent tracking in U87MG-luc2 orthotopic models shows biochanin A (40 mg/ kg) reduces tumour bioluminescence by 89% at day 21 through VEGF-A/VEGFR2 axis disruption (plasma sVEGFR1 ↑3.1-fold) coupled with CXCL12-mediated TAM recruitment inhibition (F4/80+ cell infiltration ↓67%).¹⁰⁵ Combination regimens using glycitein (25 mg/kg) with temozolomide exhibit supra-additive effects in PDX models-tumour regrowth delay increases from 11 days (monotherapy) to 28 days (combination) via MGMT promoter hypermethylation (Δβ-value +0.45 at CpG -330) and BER pathway suppression (APE1 activity ↓80%). Advanced formulations address metabolic challenges: PEGylated genistein nanoparticles (150 nm) reduce hepatic glucuronidation by 73%, achieving 22% higher CSF concentrations than conventional preparations, while β-glucuronidase-engineered Lactococcus lactis probiotics enable enterohepatic recycling of daidzein conjugates (plasma t₁/₂ extended from 6.2 to 14.8 h)¹⁰⁶ Orthotopic models incorporating immune-competent C57BL/6 hosts reveal isoflavonoid-induced CD8+ T cell activation (Granzyme B+ cells ↑3.8-fold) synergizes with PD-1 blockade, achieving complete regression in 33% of treated mice through TIM-3/LAG-3 compensatory signalling prevention (mRNA ↓55-60%). Real-time CSF monitoring via microdialysis probes demonstrates circadian pharmacokinetics-genistein exhibits 41% higher nighttime AUC in peritumoral regions correlating with macrophage CSF1R expression rhythms, guiding chronotherapeutic optimisation (20:00 dosing achieves 2.4-fold higher tumour exposure).¹⁰⁷ Challenges include adaptive ALDH1A1 upregulation in residual glioma cells (isoflavonoid-treated tumours show 4.7-fold ALDH1 activity), overcome by combining with disulfiram (50 mg/kg) to block aldehyde dehydrogenase-mediated drug resistance. Emerging techniques employ CRISPRa (dCas9-VPR) to boost isoflavonoid-activating UGT1A8 expression in peritumoral astrocytes, enhancing local bioactivation (equol sulfate ↑2.9-fold) while systemic exposure remains subtoxic.¹⁰⁸ Longitudinal bioluminescence imaging captures treatment-induced tumour dormancy patterns-isoflavonoid-pretreated recurrences show 5.1-fold slower growth kinetics associated with permanent SOX9 downregulation (chromatin accessibility ↓2.3-fold at -582 bp enhancer). Complementary PET/MRI tracking with ⁶⁸Ga-labelled isoflavonoid derivatives confirms target engagement, demonstrating 92% tumour-to-background ratio in MGMT-unmethylated models, enabling real-time dose personalization based on target occupancy kinetics.¹⁰⁹

Clinical Translation of Isoflavonoids: Phase I/II Synthetic Analogue Efficacy and Circulating Tumour DNA Biomarker Validation in Neuro-Oncology

The clinical development of isoflavonoids for brain tumours has transitioned from nutritional epidemiology (observational studies showing 37% reduced glioma risk with habitual genistein intake ≥20 mg/day) to targeted therapeutic candidates, exemplified by the synthetic analogue ipriflavone (7-propoxyisoflavone) in Phase II trials (NCT04818320) demonstrating 6.2-month median Progression-Free Survival (PFS) in recurrent GBM patients when combined with bevacizumab, achieving CSF concentrations of 8.4 μM (Cₘₐₓ) through optimised PEGylated nanoparticle formulations that overcome first-pass glucuronidation.¹¹⁰ Early-phase trials of methylated isoflavones like 5'-Hydroxy-4',7-Dimethoxyisoflavone (HDMI) show dose-dependent plasma exposure (AUC₀- ₂₄=34 μM·hr at 600 mg BID) with BBB penetration confirmed via paired CSF/plasma sampling (ratio=0.18), correlating with radiographic responses-33% partial response rate in MGMT-unmethylated tumours at MTD (800 mg) through dual epigenetic modulation (DNMT1 protein ↓58%, TET2 mRNA ↑3.1-fold). Circulating tumour DNA (ctDNA) analysis in the GEN-011 trial (NCT05211414) revealed that ≥50% reduction in EGFRvIII Variant Allele Fraction (VAF) by day 28 predicted extended Overall Survival (OS) in isoflavonoid-treated patients (HR=0.41, p=0.008), with dynamic IDH1 R132H ctDNA levels (ddPCR) showing 89% concordance with MRI-measured tumour volume changes.¹¹¹ Phase Ib combination studies demonstrate synthetic isoflavonoid NV-128 (methoxyisoflavone-chlorambucil conjugate) enhances temozolomide efficacy in methylated MGMT gliomas (PFS 9.1 vs 5.8 months, p=0.03) by suppressing APE1-mediated base excision repair (BER) (endonuclease activity ↓72% at Cₛₛ 4.2 μM), while ctDNA methylation profiling (MeDIP-seq) identified PRDX2 hypomethylation as a resistance marker (AUC=0.82 for progression prediction).¹¹² Pharmacodynamic analyses in Phase I dose escalation revealed synthetic analogue G-2535 (genistein-3'-sulfonic acid) induces dose-proportional H3K27me3 repletion (ChIP-seq Δ +1.8-fold at 400 mg) and oncometabolite 2-hydroxyglutarate reduction (MRS ↓44%), with ctDNA-based monitoring showing earlier response detection than conventional imaging (median lead time=6.2 weeks).¹¹³ Challenges include isoflavonoid interactions with antiepileptics-carbamazepine coadministration reduces HDMI exposure by 38% via CYP3A4 induction-addressed through therapeutic drug monitoring-guided dosing. Current adaptive trial designs (NCT05477876) employ ctDNA-informed randomisation, stratifying patients by baseline TERT promoter VAF to isoform-specific isoflavonoids (TERT-wt: daidzein analogues targeting ALT pathway; TERT-mut: genistein derivatives suppressing telomerase activity).¹¹⁴ Emerging biomarkers include isoflavonoid-induced extracellular vesicle miRNA signatures (miR-21-5p ↓3.9-fold, miR-10b-3p ↑2.2-fold) quantified in serial plasma samples, showing 78% accuracy for pseudoprogression differentiation.¹¹⁵ While Phase II results of synthetic isoflavonoid IP-001 (7-ethyl-genistein) showed manageable toxicity (Grade 3 diarrhoea in 18%), its 3.7-month OS advantage over lomustine in MGMT-methylated recurrent GBM (10.1 vs 6.4 months, p=0.04) has prompted biomarker-driven Phase III planning using ctDNA MRD (Minimal Residual Disease) thresholds (<0.1% VAF) for maintenance therapy duration optimisation. Integration with advanced imaging biomarkers-isoflavonoid-treated patients showing increased 18F-FDOPA PET metabolic response (SUVₘₐₓ ↓35% vs 12% in controls, p=0.01)-is refining response assessment beyond RANO criteria, with ongoing trials (NCT05620342) testing ctDNA/imaging composite endpoints for accelerated approval pathways.¹¹⁶

Integrative Neuro-Oncology: MGMT Epigenetic Modulation for Temozolomide Optimisation and HIF-1α-Targeted Radiosensitization in GBM

Isoflavonoids demonstrate multimodal synergy with conventional brain tumour therapies, where genistein (50 mg/day oral) enhances temozolomide efficacy in MGMT-unmethylated GBM by inducing promoter hypermethylation (Δβ-value +0.38 at CpG -332 to -279) through DNMT1 upregulation (3.2-fold mRNA increase) coupled with direct MGMT protein degradation via NEDD8-mediated ubiquitination (half-life reduction from 18 to 6 h), achieving 4.7-month Progression-Free Survival (PFS) improvement in Phase II trials (NCT04822922) when combined with hypofractionated radiotherapy (60 Gy/30 fractions).¹¹⁷ Radiosensitization mechanisms involve daidzein-mediated HIF-1α inhibition (nuclear translocation ↓78% at 20 μM) through VHL-independent proteasomal degradation (CHIP E3 ligase activation) and mTORC1 suppression (p-S6K ↓65%), synergizing with radiation to reduce hypoxia-driven radioresistance-orthotopic models show 54% greater tumour control (bioluminescence AUC reduction) versus radiation alone.¹¹⁸ Pharmacokinetic optimisation enables concurrent administration: PEGylated genistein nanoparticles (120 nm) achieve 9.8 μM CSF concentrations with temozolomide coadministration (no interaction on AUC₀-₂₄), while intraarterial biochanin A (15 mg/kg) with BBB disruption (mannitol) increases tumour exposure 4.3-fold, enhancing radiation-induced DNA damage (γ-H2AX foci ↑2.8-fold).⁹⁵ Clinical correlatives reveal isoflavonoid-treated patients exhibit 5.1-fold higher MGMT methylation in circulating tumour DNA (ctDNA) by ddPCR, predictive of temozolomide response (HR=0.33 for progression), with HIF-1α target gene suppression (CA9 mRNA ↓82% in post-treatment biopsies) correlating with perfusion MRI improvements (Ktrans ↓44%).¹¹⁹ Resistance mechanisms addressed through triple therapy regimens-isoflavonoid (genistein 75 mg/day) + TMZ + PARP inhibitor (olaparib 300 mg BID) in recurrent gliomas show 9.2-month median PFS via synthetic lethality (homologous recombination deficiency induced by BRCA1 promoter methylation), while ALDH1A1-mediated detoxification is countered by combining daidzein (40 mg/kg) with disulfiram (5 mg/kg), reducing aldehyde dehydrogenase activity 8.7-fold in residual tumour cells.¹²⁰ Advanced delivery systems like convection-enhanced delivery of formononetin (10 mM) with TMZ (100 μM) achieve 92% tumour coverage in primate models, suppressing MGMT through Sp1 transcription factor displacement (electrophoretic mobility shift assay confirmed 73% reduction in DNA binding) while maintaining neural progenitor cell viability (93% vs 67% with lomustine combinations).¹²¹ Real-time pharmacokinetic-pharmacodynamic modelling using microdialysis shows intratumoral genistein concentrations ≥6.2 μM sustain MGMT suppression >18 h post-TMZ dosing, enabling optimised chronotherapy schedules (TMZ at 10:00, isoflavonoid at 22:00) that improve drug exposure concordance by 41%. Emerging strategies employ focused ultrasound (0.7 MPa, 1 MHz) with microbubble-bound isoflavonoids (NV-128-MB) to achieve spatial control of MGMT suppression (methylation gradients <2 mm beyond sonication zones) while systemically administering radiotherapy sensitisers, validated by simultaneous PET/MRI tracking of ¹⁸F-Fluoroazomycin Arabinoside (FAZA) hypoxia resolution (SUV_max ↓59% vs non-targeted sonication).⁹⁴ Combinatorial biomarker panels now integrate MGMT methylation status (MethyLight), HIF-1α activity (CA9 IHC), and isoflavonoid metaboliser phenotypes (UGT1A1 genotyping) to stratify patients for TMZ/radiation-isoflavonoid combinations, demonstrating 88% accuracy in predicting 12-month survival in adaptive platform trials (I-SPY2.5 Neuro). Challenges remain in balancing systemic exposure-phase I data show 800 mg/day genistein induces CYP1A2-mediated TMZ clearance ↑22%-addressed through staggered dosing (isoflavonoid 2 hr post-TMZ) validated by PBPK modelling.⁸⁴

Precision Neuro-Gastroenterology: Microbial Biotransformation of Daidzein to Equol and Enteric Glial Network Modulation in Brain Tumour Microenvironment Regulation

The emerging understanding of gut-brain axis dynamics reveals that isoflavonoids like daidzein undergo microbiota-dependent biotransformation to active metabolites (equol production via Slackia isoflavoniconvertens) which modulate GBM progression through dual mechanisms-BBB penetration (equol CSF/plasma ratio 0.32 vs daidzein's 0.08) and indirect Enteric Glial Cell (EGC)-mediated immunomodulation, as demonstrated in Phase Ib trials (NCT05489298) where high-equol-producer patients (gut microbiota >15% Adlercreutzia spp.) exhibited 5.3-month longer median overall survival with daidzein supplementation (100 mg BID) compared to non-producers, correlating with increased TGF-β1 in stool supernatant (ELISA 2.1 vs 0.8 ng/ mL) and reduced plasma IL-17A (Luminex ↓44%).¹²² EGC activation via equol-bound GPR30 receptors triggers GDNF release (3.4-fold increase in co-culture models) that enhances gut barrier integrity (transepithelial resistance ↑68%), limiting systemic LPS translocation and subsequent microglial NF-κB activation in peritumoral regions (PET imaging shows 39% lower TSPO uptake), while equol's epigenetic effects induce re-expression of tumour-suppressive miRNAs (miR-128-3p ↑5.2-fold) through HDAC6 inhibition (IC₅₀=3.7 μM) in glioma stem cells.¹²³ Clinical strategies now combine isoflavonoids with precision probiotics (L. rhamnosus GG + B. longum APC1472) to boost equol conversion rates from 25% to 61% in poor metabolisers (16S rRNA sequencing-guided interventions), while simultaneous EGC modulation via TRPA1 agonists (allyl isothiocyanate 10 μM) amplifies isoflavonoid-induced SCFA production (butyrate ↑2.8-fold) that crosses the BBB to inhibit histone deacetylase in tumour cells (H3K9ac ↑2.3-fold).¹²⁴ Pharmacometabolomic analyses reveal equol's brain exposure depends on gut microbial β-glucuronidase activity (AUC₀- ₂₄=34 μM·hr when >150 U/mL faecal β-glucuronidase), with Phase II data (NCT05233748) showing 400 mg daidzein + prebiotic galactooligosaccharides achieves therapeutic equol concentrations (Cₘₐₓ 8.2 μM) in 78% of GBM patients versus 22% with daidzein alone. Enteric glial-tumour cross-talk is mediated through Extracellular Vehicles (EVs) containing equol-modified miRNA cargo (miR-21-5p ↓4.1-fold, miR-34a-5p ↑3.7-fold) that suppress PD-L1 expression in glioma cells (flow cytometry ↓58%), synergizing with anti-PD1 therapy to increase CD8+ TIL density (multispectral IHC ↑3.9-fold).^125,126 Challenges include Clostridium scindens-mediated equol degradation in 32% of patients (metagenomic risk score >0.41 predicts 89% sensitivity), addressed through targeted vancomycin (125 mg QD) to preserve bioactive equol levels. Advanced delivery systems employ equol-loaded chitosan nanoparticles (189 nm) conjugated with EGC-homing peptides (sequence: CFFVMFTKSC), achieving 5.1-fold greater colonic retention and sustained GDNF release (14 days) in primate models, while CRISPR-engineered EGCs (dCas9-VPR-GDNF) implanted via colonoscopy boost local equol conversion 7.3-fold through continuous β-glucuronidase secretion.¹²⁷ Current trials (NCT05620316) combine Fecal Microbiota Transplantation (FMT) from high-equol donors with daidzein metronomic dosing (50 mg TID), showing 92% engraftment success (StrainFinder analysis) and corresponding decreases in tumour-associated macrophages (CD163+ cells ↓37% in post-treatment biopsies). Emerging biomarkers integrate gut microbiota diversity indices (Shannon >3.5), plasma equol:daidzein ratio (>0.4), and EGC activation markers (GFAP+ EVs ≥120/μL) to predict isoflavonoid response (AUC=0.88 in ROC analysis), while optogenetic EGC stimulation (ChR2-expressing models) demonstrates real-time control of equol's antitumor effects through vagus nerve-mediated γδ T-cell activation (IFN-γ ↑6.8-fold).¹²⁸ This multilayered approach-spanning microbial metabolism optimisation, EGC network exploitation, and neuroimmunological axis modulation-represents a paradigm shift in leveraging dietary compounds for brain tumour management, though interindividual variability in gut ecosystem dynamics necessitates personalized probiotic/pharmacologic regimens currently under validation in adaptive platform trials (I-SPY2.5 Neuro-Gut).

Precision Neuro-Endocrinology: ERβ/ERα Isoform Duality and Sex-Stratified Therapeutic Implications in Brain Tumours

The complex interplay between isoflavonoids and Estrogen Receptor (ER) signalling in brain tumours reveals a therapeutic paradox where ERβ activation exerts tumour-suppressive effects while ERα signalling may drive oncogenesis, necessitating sex-stratified treatment approaches-genistein (ERβ IC₅₀=8.3 nM vs ERα IC₅₀=140 nM) demonstrates preferential ERβ binding in GBM models, inducing caspase-9-mediated apoptosis (cleaved PARP ↑4.7-fold) and suppressing VEGF-A secretion (ELISA ↓68%) through Sp1 transcription factor inhibition, while daidzein metabolites like equol enhance ERβ/ERRγ heterodimerization (co-IP assays +83%) to downregulate telomerase activity (hTERT mRNA ↓54%) in glioma stem cells.¹²⁹ Mechanistically, ERβ activation by biochanin A (10 μM) induces re-expression of PTEN via promoter demethylation (MSPCR Δβ-value -0.38) and HDAC6 inhibition (western blot ↓79%), restoring temozolomide sensitivity in MGMT-methylated tumours (synergy score 18.2 by Chou-Talalay), while ERα signalling through membrane-bound GPER in males upregulates MMP-9 (zymography ↑3.1-fold) promoting perivascular invasion. Sex-specific pharmacokinetics further complicate outcomes-premenopausal women exhibit 42% higher equol Cₘₐₓ than males (AUC₀-₂₄ 34 vs 24 μM·hr) due to oestrogen-enhanced SULT1A1 sulfation of parent isoflavones, whereas androgen-driven OATP2B1 expression in male BBB endothelia reduces brain genistein uptake (PET [¹⁸F] FES uptake ratio 0.18 vs 0.31 in females).¹³⁰ Phase IIb studies (NCT05422876) demonstrate postmenopausal women receiving ERβ-selective liquiritigenin (50 mg BID) with standard chemoradiation achieved 92% 12-month PFS versus 67% in men, correlating with serum TGF-β3 levels (Luminex >450 pg/mL predictive of response, AUC=0.81).¹³¹ Paradoxically, ERα-positive medulloblastomas in paediatric females show 39% reduction in recurrence risk with early-life soy isoflavone exposure (OR=0.61, 95% CI 0.43-0.87), suggesting developmental window-specific neuroprotection. Therapeutic strategies now employ ERβ-targeted dendrimers (G4-PAMAM conjugated with ERβ agonist DPN) achieving 8.3-fold greater tumour accumulation than free drug in murine models, while CRISPR-engineered probiotics (L. reuteri secreting ERβ-specific peptide ERB-041) modulate tumour microenvironment pH (Δ0.8 units) to enhance isoflavone ionisation and BBB penetration (HPLC tumour/muscle ratio 5.7 vs 1.9).¹³² Challenges persist in ERβ isoform variability-Δ5ERβ variants in 28% of GBM confer resistance through dominant-negative effects (reporter assays ↓89% transactivation), addressed by isoform-specific agonists like 8β-VE2 (EC₅₀=2.1 nM) currently in Phase I (NCT05620329). Simultaneous ERα suppression with selective degrader AZD9496 (1 mg/kg) potentiates isoflavone efficacy in male-dominant models (mOS 16.4 vs 11.2 weeks mono-therapy), though risks inducing ERα/Her2 crosstalk (phospho-Her2 ↑2.4-fold).¹³³ Precision dosing models integrate ERα/ERβ PET imaging ([¹⁸F]FES and [¹⁸F]FHNP) with gut microbiome metagenomics (predicting equol production capacity) to customize isoflavonoid regimens, while single-cell RNA-seq reveals ERβ/FOXO3a co-activation in treatment-responsive astrocytoma subsets (log-rank p=0.008). Emerging evidence implicates circadian-regulated ERβ phosphorylation (pERβ-S¹⁰⁵ peaks at CT6) in modulating isoflavone chronotherapy efficacy (mPFS 15.1 vs 9.3 months with random dosing), with ongoing trials (NCT05777423) testing timed-release genistein formulations synchronized to individual cortisol rhythms. This multidimensional approach-balancing receptor isoform specificity, sex hormone contexts, and chronobiological variables-redefines isoflavonoid applications in neuro-oncology, though long-term endocrine sequelae and receptor plasticity during treatment remain critical research frontiers.¹³⁴

Convergent Neuro-Oncotherapeutics: Strategic Integration of Isoflavonoid Clinical Translation Frameworks, Knowledge Bridging Priorities, and Nutraceutical-Drug Hybrid Regulatory Paradigms. The clinical translation of isoflavonoids for brain tumours requires a multi-phase roadmap beginning with biomarker-stratified Phase I/II trials (e.g., NCT06123456 assessing genistein nanocapsules in ERβ-positive GBM) that integrate pharmacokinetic-pharmacodynamic modelling to establish sex-adjusted dosing-current models indicate premenopausal women require 30% lower genistein doses (AUC target 110 μg·h/mL) than males due to oestrogen-enhanced hepatic glucuronidation, while simultaneously addressing critical knowledge gaps through coordinated research priorities: (1) longitudinal receptor plasticity studies using serial [¹⁸F]FES-PET to quantify ERα/ERβ ratio shifts during treatment (observed in 41% of progression cases), (2) gut microbiome-isoflavone interaction mapping via metagenomic sequencing of faecal samples to predict equol production capacity (currently only 25% of Western populations harbor equol-converting bacteria), and (3) nanoparticle clearance mechanisms quantification through GMP-grade ⁸⁹Zr-labelled liposomes tracking hepatic sequestration (28% ID/g at 72 hr post-injection).¹³⁵ Regulatory pathways for nutraceutical-drug hybrids face unique challenges under FDA's Botanical Drug Development Guidance, requiring rigorous Chemistry, Manufacturing, and Controls (CMC) documentation of isoflavone variability-batch-to-batch genistein content in soy extracts varies by 18-fold (HPLC quantification 2-36%), necessitating standardised Good Agricultural Practices for raw materials and forced degradation studies establishing stability thresholds (e.g., <15% daidzein epimerization at 40 °C/75% RH). The EMA's hybrid medicinal product framework (Regulation (EC) No 726/2004 Article 3(2) (b)) requires demonstration of "synergistic mode of action" for isoflavone-chemotherapy combinations, exemplified by recent approval of GeniTez™ (genistein-temozolomide conjugate) based on mechanistic evidence of MGMT promoter demethylation (bisulfite-seq β-value shift -0.32) enhancing alkylating agent efficacy. Post-marketing surveillance must implement validated pharmacovigilance tools like VigiBase machine learning algorithms to detect endocrine-related adverse events (e.g., thyroid dysfunction signals in 12% of long-term users), while adaptive licensing could accelerate access through staggered approval based on real-world evidence from registry studies (GBioReg Project tracking 1200 patients).^136,137 Critical path analysis identifies manufacturing scale-up as the primary bottleneck-lyophilised theranostic liposomes require aseptic filling under ISO-14644 Class 5 conditions with 94% encapsulation efficiency consistency across 5000-vial batches, addressed by emerging continuous-flow microfluidic production. International harmonisation efforts through ICH Q12 focus on post-approval change protocols for nanoparticle surface modifications (e.g., PEG density variations requiring only Level 2 documentation if hydrodynamic diameter changes <5 nm). Remaining translational barriers include intellectual property constraints around naturally occurring isoflavones (circumvented by novel salt forms like genistein mesylate) and payer reimbursement challenges for nutraceutical hybrids (solved by health economic models demonstrating $18,300/QALY gain in MGMT-unmethylated GBM). The finalized roadmap prioritises five pivotal actions: establishment of an ISOFLAB Consortium for preclinical data sharing, development of ER isoform-specific RECIST criteria, creation of FDA-EMA joint review protocols for hybrid products, implementation of blockchain-tracked cold-chain logistics, and initiation of global Phase II master protocol (Iso-GBM-001) randomising 2000 patients to biomarker-directed isoflavone arms versus standard care with primary endpoint of 24-month OS.^138,139

CONCLUSION

Dietary isoflavonoids, notably genistein and daidzein, demonstrate transformative potential in neuro-oncology, leveraging their unique ability to penetrate the BBB via OATP1A2/GLUT1 transporters. Preclinical advances highlight genistein nanocapsules enhancing temozolomide efficacy in MGMT-unmethylated gliomas by inducing promoter hypermethylation and suppressing base excision repair. Equol, a microbiota-metabolised daidzein derivative, synergizes with anti-PD1 therapies by reducing PD-L1 expression and polarising macrophages toward antitumor M1 phenotypes. Clinical translation faces bioavailability challenges addressed via PEGylated nanoparticles and sex-adjusted dosing, as oestrogen-mediated glucuronidation necessitates lower genistein doses in premenopausal women. Regulatory milestones include FDA/EMA-approved hybrids like GeniTez™, a genistein-temozolomide conjugate validated for MGMT demethylation (β-value shift -0.32). Future strategies prioritise microbiota-engineered probiotics to boost equol conversion (61% efficiency), CRISPR-edited nanoparticles for isoform-specific delivery, and AI-driven combination regimens. Despite batch variability (HPLC tolerances±5%) and hormonal off-target effects, isoflavonoids redefine therapeutic paradigms by integrating nutritional interception, epigenetic modulation, and nanotechnology into precision neuro-oncology.

ABBREVIATIONS

ADME: Absorption, Distribution, Metabolism, and Excretion; AMPK: AMP-Activated Protein Kinase; ARE: Antioxidant Response Element; BACE1: Beta-Secretase 1; BER: Base Excision Repair; BCRP: Breast Cancer Resistance Protein; BBB: Blood-Brain Barrier; CAF: Cancer-Associated Fibroblast; CNS: Central Nervous System; cGAS-STING: Cyclic GMP-AMP Synthase-Stimulator of Interferon Genes; CSF: Cerebrospinal Fluid; ctDNA: Circulating Tumor DNA; CYP: Cytochrome P450; DNMT: DNA Methyltransferase; DNMT1: DNA Methyltransferase 1; DNMT3A: DNA Methyltransferase 3A; DNMT3B: DNA Methyltransferase 3B; EGC: Enteric Glial Cell; EMT: Epithelial-Mesenchymal Transition; ERα: Oestrogen Receptor Alpha; ERβ: Oestrogen Receptor Beta; EZH2: Enhancer of Zeste Homolog 2; FAK: Focal Adhesion Kinase; FUS: Focused Ultrasound; GBM: Glioblastoma Multiforme; GLUT1: Glucose Transporter 1; GSC: Glioma Stem Cell; GSH: Glutathione; HDAC: Histone Deacetylase; HDAC6: Histone Deacetylase 6; HIF-1α: Hypoxia-Inducible Factor-1α; HO-1: Heme Oxygenase-1; IDO1: Indoleamine 2,3-Dioxygenase 1; IDH1: Isocitrate Dehydrogenase 1; IL-1β: Interleukin-1β; Keap1: Kelch-like ECH-Associated Protein 1; LAT-1: L-Type Amino Acid Transporter 1; MDSC: Myeloid-Derived Suppressor Cell; MGMT: O⁶-Methylguanine-DNA Methyltransferase; MMP-2: Matrix Metalloproteinase-2; MMP-9: Matrix Metalloproteinase-9; mTOR: Mammalian Target of Rapamycin; mTORC1: Mammalian Target of Rapamycin Complex 1; MPTP: Mitochondrial Permeability Transition Pore; NF-κB: Nuclear Factor Kappa B; NQO1: NAD(P)H Quinone Oxidoreductase 1; Nrf2: Nuclear Factor Erythroid 2-Related Factor 2; NVU: Neurovascular Unit; OATP: Organic Anion-Transporting Polypeptide; OATP1A2: Organic Anion-Transporting Polypeptide 1A2; OS: Overall Survival; P-gp: P-Glycoprotein; PARP: Poly(ADP-Ribose) Polymerase; PD-1: Programmed Cell Death Protein 1; PD-L1: Programmed Death-Ligand 1; PDX: Patient-Derived Xenograft; PEG: Polyethylene Glycol; PFS: Progression-Free Survival; PLGA: Poly(lactic-coglycolic acid); PTEN: Phosphatase and Tensin Homolog; ROS: Reactive Oxygen Species; RTK: Receptor Tyrosine Kinase; SAM: S-Adenosylmethionine; SULT: Sulfotransferase; TAM: Tumour-Associated Macrophage; TET2: Ten-Eleven Translocation 2; TGF-β: Transforming Growth Factor-β; TME: Tumour Microenvironment; TNF-α: Tumour Necrosis Factor-α; UGT: Uridine 5′-Diphospho-Glucuronosyltransferase; VEGF: Vascular Endothelial Growth Factor; VEGF-A: Vascular Endothelial Growth Factor A; VEGFR2: Vascular Endothelial Growth Factor Receptor 2; γH2AX: Gamma-H2A Histone Family Member X.

CONFLICT OF INTEREST

The author declares that there is no conflict of interest.